US stock night market fluctuations: Regencell Bioscience rose 3.71% in the night market

U.S. Stock Night Market Movements

Regencell Bioscience rose 3.71% in the night market. Based on recent important news:

1. On June 17, Regencell Bioscience announced a stock split, expanding the number of circulating shares, leading retail investors to flock in, and the stock price soared by 283.13%.

2. On June 18, analysts stated that the surge in Regencell Bioscience's stock price was seen as driven by speculation, with a very low proportion of circulating shares, making the stock price prone to volatility.

3. On June 16, Regencell Bioscience issued a risk warning, stating that it had not generated revenue from its traditional Chinese medicine candidate formulations, and the soaring valuation raised concerns.

Stocks with High Trading Volume in the Industry

Novo Nordisk fell 0.25% in the night market. Based on recent important news:

1. On July 29, Novo Nordisk issued a profit warning and appointed a new CEO, causing the stock price to plummet by 23%, with a market value evaporating by $70 billion.

2. On July 31, HSBC downgraded Novo Nordisk's rating to "Hold," lowering the target price from 680 Danish Krone to 360 Danish Krone, with a stock price decline of 2.5%.

3. On July 30, analysts warned of intensified competition in the U.S. generic drug market, leading to a continued decline in Novo Nordisk's stock price.

Eli Lilly fell 0.28%, with a trading volume of 53,200. Based on recent important news:

1. On July 29, Novo Nordisk's stock price plummeted by 21.83%, impacting Eli Lilly's stock price, which fell by 5.59%. Novo Nordisk lowered its earnings expectations, heightening market concerns.

2. On July 31, Eli Lilly's diabetes drug trial did not meet expectations, affecting market confidence.

3. On August 1, Trump demanded drug companies to lower prices, causing Eli Lilly's stock price to turn down by 0.7%.

Pfizer's stock price fell nearly 5%. Based on recent important news:

1. On August 1, Trump demanded 17 drug companies to lower drug prices within 60 days, resulting in a nearly 5% drop in Pfizer's stock price.

2. On July 31, Trump revived the "Most Favored Nation" policy, requiring drug prices to be lower than those in other countries, leading to a general decline in stock prices for Pfizer and other companies.

3. On July 30, the FDA announced a halt in the production of some Pfizer drugs, leading to a negative market reaction